Conivaptan hydrochloride
Based on 14 publication(s) in Google Scholar
Conivaptan hydrochloride (YM 087) is an orally active dual vasopressin V1a/V2 receptor antagonist with Ki values of 0.48 nM and 3.04 nM for vasopressin V1a receptor and V2 receptor, respectively. Conivaptan hydrochloride competitively and reversibly blocks vasopressin-mediated antidiuresis, vasoconstriction, and cellular hypertrophy, while inhibiting CYP3A4. Conivaptan hydrochloride inhibits vasopressin-induced intracellular calcium, cAMP, and mitogen-activated kinase activation in vascular smooth muscle cells and cardiomyocytes. Conivaptan hydrochloride induces water diuresis while improving hemodynamics in heart failure models, reducing left ventricular end-diastolic pressure, vascular resistance, and organ weight. Conivaptan hydrochloride is used for research on hyponatremia and congestive heart failure.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.95%
- No. CAS: 168626-94-6
- Fòrmula: C32H27ClN4O2
- Peso molecular:535.04
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-13262
LumacaftorCFTR Modulator -
HY-15531
VenetoclaxBCL-2 Inhibitor -
HY-10159
NilotinibBcr-Abl Inhibitor -
HY-18345
SR 49059Vasopressin V1a Antagonist -
HY-13613
Dutasteride5α-Reductase Isozyme Inhibitor -
HY-15306
EltrombopagTPO Receptor Agonist -
HY-17007
SaquinavirHIV Protease Inhibitor -
HY-B0670A
Dihydroergotamine mesylate5-HT1B/1D Agonist -
HY-P0049
ArgipressinVasopressin Receptor Agonist -
HY-18346
MozavaptanVasopressin V2 Receptor Antagonist -
HY-16562
IrinotecanTopoisomerase I Inhibitor -
HY-14185
LixivaptanV2 Antagonist
Publications Citing Use of MedChemExpress (MCE) Conivaptan hydrochloride
More- Cell. 2026 May 28;189(11):3444-3464.e28. [Abstract]
- Nat Commun. 2025 Nov 4;16(1):9734. [Abstract]
- J Transl Med. 2025 Jan 22;23(1):103. [Abstract]
- J Med Chem. 2024 Apr 11;67(7):5935-5944. [Abstract]
- J Med Chem. 2022 Jul 14;65(13):9295-9311. [Abstract]
- Biomed J. 2020 Aug;43(4):368-374. [Abstract]
- Eur J Pharmacol. 2020 Aug 5:880:173157. [Abstract]
- Front Pharmacol. 2019 Nov 15:10:1380. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- Neurogastroenterol Motil. 2019 Feb;31(2):e13493. [Abstract]
- Dig Dis Sci. 2022 Aug;67(8):3683-3692. [Abstract]
- Biomed Pharmacother. 2025 Aug:189:118246. [Abstract]
- SSRN. 2025 Jun 18.
- SSRN. 2023 May 30.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
Ver todos los productos específicos de isoformas Vasopressin Receptor
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
V1a Receptor 0.48 nM (Ki) |
V2 Receptor 3.04 nM (Ki) |
CYP3A4 |
In Vitro
Conivaptan hydrochloride binds to vasopressin V1a receptors (Ki = 0.48 nM) and vasopressin V2 receptors (Ki = 3.04 nM) in a competitive and reversible manner, and shows almost no activity against vasopressin V1b receptors[1].
Conivaptan hydrochloride inhibits vasopressin-triggered intracellular calcium elevation in vascular smooth muscle cells (IC50 = 1.16 nM) and simultaneously inhibits vasopressin-induced cAMP accumulation (IC50 = 17.3 nM)[1].
Conivaptan hydrochloride binds with high affinity to canine platelet V1a receptors (Ki = 0.6 nM) and canine kidney V2 receptors (Ki = 0.7 nM), binds to rhesus monkey liver V1a receptors (Ki = 26 nM) and rhesus monkey kidney V2 receptors (Ki = 10 nM), and inhibits AVP binding to human cloned V1a receptors (Ki = 6.3 nM) and V2 receptors (Ki = 1.1 nM) in COS1 cells.
Conivaptan hydrochloride inhibits AVP-induced increases in Ca2+ and cAMP in COS1 cells expressing human receptors, with IC50 values of 2.0-14.3 nM; it inhibits AVP-induced Ca2+, mitogen-activated kinase, and protein synthesis in rat cardiomyocytes expressing V1a receptors; and it inhibits AVP-induced proliferation and hypertrophy of vascular smooth muscle cells in growth-arrested rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 168626-94-6
-
Appearance Solid
-
Peso molecular 535.04
-
Fòrmula C32H27ClN4O2
-
Color White to off-white
-
SMILES
O=C(C1=CC=CC=C1C2=CC=CC=C2)NC3=CC=C(C(N4CCC(N=C(C)N5)=C5C6=CC=CC=C64)=O)C=C3.Cl
-
Synonyms
YM 087
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Cell
2026 May 28;189(11):3444-3464.e28. PMID: 41923641 -
Nat Commun
2025 Nov 4;16(1):9734. PMID: 41188237
Conivaptan hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 4;16(1):9734. [Abstract]
Effects of pocket residue mutations in V2R on the antagonistic activity of Conivaptan hydrochloride.
-
J Transl Med
Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma. [Abstract]2025 Jan 22;23(1):103. PMID: 39844299 -
J Med Chem
Long-Residence Time Peptide Antagonist for the Vasopressin V2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease. [Abstract]2024 Apr 11;67(7):5935-5944. PMID: 38509003 -
J Med Chem
Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease. [Abstract]2022 Jul 14;65(13):9295-9311. PMID: 35579344 -
Biomed J
2020 Aug;43(4):368-374. PMID: 32563698 -
Eur J Pharmacol
Revisit ligand-receptor interaction at the human vasopressin V2 receptor: A kinetic perspective. [Abstract]2020 Aug 5:880:173157. PMID: 32360346
Conivaptan hydrochloride purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2020 Aug 5:880:173157. [Abstract]
All compounds produced concentration-dependent inhibition of specific Conivaptan hydrochloride-red binding.
Conivaptan hydrochloride purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2020 Aug 5:880:173157. [Abstract]
Saturation experiments for Conivaptan hydrochloride-red (0.1-100 nM, final concentration) binding to the SNAP-tagged HEK293hV2R cells at 25 ℃ and 37 ℃; total binding, non-specific binding and specific binding are shown. Nonspecific binding was determined in the presence of 100 μM Conivaptan hydrochloride and represented less than 10% of the total Conivaptan hydrochloride-red binding. Data are from three independent experiments each performed in duplicate.
Conivaptan hydrochloride purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2020 Aug 5:880:173157. [Abstract]
Equilibrium and kinetic binding profiles of conivaptan-red at the vasopressin V2 receptor.
-
Front Pharmacol
Intradermal Injection of Oxytocin Aggravates Chloroquine-Induced Itch Responses via Activating the Vasopressin-1a Receptor/Nitric Oxide Pathway in Mice. [Abstract]2019 Nov 15:10:1380. PMID: 31824317
Conivaptan hydrochloride purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Nov 15:10:1380. [Abstract]
The OT-mediated enhancement of CQ-induced scratching behavior was significantly suppressed in mice pretreated with the V1AR antagonist Conivaptan hydrochloride (1 µg/site).
-
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
Neurogastroenterol Motil
Vasopressin augments TNBS-induced colitis through enteric neuronal V1a receptor-mediated COX-2-dependent prostaglandin release from mast cells in mice. [Abstract]2019 Feb;31(2):e13493. PMID: 30334342 -
Dig Dis Sci
A New Role for Conivaptan in Ulcerative Colitis in Mice: Inhibiting Differentiation of CD4+T Cells into Th1 Cells. [Abstract]2022 Aug;67(8):3683-3692. PMID: 34751838 -
Biomed Pharmacother
Identification of nsp16 inhibitors of SARS -CoV-2, SARS -CoV-1 and MERS-CoV from FDA-approved drugs using in silico and in vitro methods. [Abstract]2025 Aug:189:118246. PMID: 40543162 -
-
Solvente y solubilidad
In Vitro:
DMSO : ≥ 100 mg/mL (186.90 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.67 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.67 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Calcium Spark Assay
Calcium sparks are localized, transient increases in intracellular calcium concentration ([Ca2+]i) that occur in cardiac myocytes and represent elementary events underlying excitation-contraction coupling. These events are generated by the coordinated opening of clusters of ryanodine receptors (RyRs) on the sarcoplasmic reticulum membrane, leading to a brief release of Ca2+ into the cytosol. The detection and analysis of calcium sparks provide insights into the mechanisms of calcium handling and signaling in cardiac cells. Imaging techniques using fluorescent calcium indicators such as Fluo-3 are employed to visualize these subcellular calcium transients with high spatial and temporal resolution. The protocol is based on established methodologies described in primary literature for both experimental measurement and automated analysis of calcium sparks.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
Pureza y Documentación
-
Ficha de datos (284 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8690 mL | 9.3451 mL | 18.6902 mL | 46.7255 mL |
| 5 mM | 0.3738 mL | 1.8690 mL | 3.7380 mL | 9.3451 mL | |
| 10 mM | 0.1869 mL | 0.9345 mL | 1.8690 mL | 4.6725 mL | |
| 15 mM | 0.1246 mL | 0.6230 mL | 1.2460 mL | 3.1150 mL | |
| 20 mM | 0.0935 mL | 0.4673 mL | 0.9345 mL | 2.3363 mL | |
| 25 mM | 0.0748 mL | 0.3738 mL | 0.7476 mL | 1.8690 mL | |
| 30 mM | 0.0623 mL | 0.3115 mL | 0.6230 mL | 1.5575 mL | |
| 40 mM | 0.0467 mL | 0.2336 mL | 0.4673 mL | 1.1681 mL | |
| 50 mM | 0.0374 mL | 0.1869 mL | 0.3738 mL | 0.9345 mL | |
| 60 mM | 0.0312 mL | 0.1558 mL | 0.3115 mL | 0.7788 mL | |
| 80 mM | 0.0234 mL | 0.1168 mL | 0.2336 mL | 0.5841 mL | |
| 100 mM | 0.0187 mL | 0.0935 mL | 0.1869 mL | 0.4673 mL |
Conivaptan hydrochloride Related Classifications
HY-18347A Related Classifications
Powered by Bioz